ConductScience.org, home

Trial · NCT04746911

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

NCT04746911, Phase 2, Completed, Arcutis Biotherapeutics, Inc.

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216). Trials, record NCT04746911. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04746911

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
NCT number
NCT04746911
Status
Completed
Phases
Phase 2
Enrollment
10 participants, actual
Lead sponsor
Arcutis Biotherapeutics, Inc.
Conditions
Psoriasis, Plaque Psoriasis
Interventions
ARQ-151 cream 0.3%
First posted
2021-02-10
Last updated
2026-08-07

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryPlasma Concentration of Roflumilast Following Daily Application of Roflumilast Cream 0.3%Weeks 2 and 4: 1 hour predoseThe plasma concentration of roflumilast at Weeks 2 and 4 is reported.
PrimaryPlasma Concentration of Major N-oxide Metabolite Following Daily Application of Roflumilast Cream 0.3%Weeks 2 and 4: 1 hour predoseThe plasma concentration of the major N-oxide metabolite of roflumilast at Weeks 2 and 4 is reported.
PrimaryNumber of Participants With an Adverse Event (AE)Up to 4 weeksThe number of participants with an AE during the treatment period is reported. An AE is any untoward medical
PrimaryNumber of Participants With Application Site ReactionsUp to 4 weeksThe number of subjects that experience an application site skin reaction by investigator assessment or application site reactions reported as AEs is reported.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMIDListed as
40862624DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04746911

GET https://conductscience.org/api/trials/v1/NCT04746911/registered